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Subtle metabolic changes precede and accompany chronic vascular complications, which are the
primarycausesofprematuredeathindiabetes.Toobtainamultimetabolitecharacterizationofthese
high-risk individuals, we measured proton nuclear magnetic resonance (
1H NMR) data from the
serum of 613 patients with type I diabetes and a diverse spread of complications. We developed a
new metabonomics framework to visualize and interpret the data and to link the metabolic proﬁles
to the underlying diagnostic and biochemical variables. Our results indicate complex interactions
between diabetic kidney disease, insulin resistance and the metabolic syndrome. We illustrate how
a single
1H NMR protocol is able to identify the polydiagnostic metabolite manifold of type I diabetes
and how its alterations translate to clinical phenotypes, clustering of micro- and macrovascular
complications, and mortality during several years of follow-up. This work demonstrates the diffuse
nature of complexvasculardiseases andthe limitations ofsingle diagnostic biomarkers.However, it
also promises cost-effective solutions through high-throughput analytics and advanced computa-
tional methods, as applied here in a case that is representative of the real clinical situation.
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Introduction
Type I diabetes is caused by an autoimmune reaction against
the insulin-producing pancreatic b-cells and subsequent
disturbance of normal blood glucose metabolism. Insulin
replacement therapycures the acute symptoms, but is not able
tomatchthenaturalresponsetorisingorfallingglucoselevels.
Thispersistentmetabolicimbalanceislinkedtohighincidence
of vascular complications such as diabetic kidney disease
(DKD) (Finne et al, 2005), diabetic retinal disease (DRD) (Roy
et al, 2004) and macrovascular diseases (MVDs) (Libby et al,
2005), all of which are co-occurring in vulnerable patients
(Groop et al, 2005; Thorn et al, 2005; Ala-Korpela, 2007). The
diagnosis, risk assessment and treatment of these conditions
are currently determined by a number of biochemical and
clinical variables, although none of these are conclusive on its
own (Soedamah-Muthu et al, 2004; Stadler et al, 2006).
Furthermore, the simultaneous clustering of complications
and metabolic risk factors has not been studied by high-
throughput analytical techniques that could reveal the
multidimensional metabolic state of an individual more
effectively.
Thestandarddifferentialdiagnosticsinmedicinemaynotbe
sufﬁcient in detecting complex perturbations of biological
systems (Zenker et al, 2007). Conditions such as insulin
resistance and atherosclerosis stem from nonlinear interactive
pathways between the genes (Hakonarson et al, 2007), gene
expression (Sieberts and Schadt, 2007), metabolic environ-
ment (Goodacre, 2007) and the symbiotic microﬂora (Martin
etal,2007).Topinpoint thenodesandtheirrolesinthedisease
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dimensional quantitative data—a direct consequence of the
curse of dimensionality. The genome-wide association studies
have shown that this can be achieved at the DNA level
(Frayling, 2007; Wellcome Trust Case Control Consortium,
2007). However, for personalized risk assessment and treat-
ment the genetic approach is limited, as it does not take into
account the dynamic environment, unlike the metabonomics
approach (Nicholson and Wilson, 2003; Clayton et al, 2006),
which has gained popularity as analytical technologies
are evolving (Nicholson, 2006; Ala-Korpela, 2007; Salek
et al, 2007).
Diabetic complications pose a difﬁcult challenge to public
health care, as populations grow older and life style becomes
more sedentary and energy-rich (Reunanen et al, 2000). For
this reason, we are aiming at new screening methods and
metaboliccharacterizationtoolstoﬁndthevulnerablepatients
at an early stage when preventive treatment is still effective
(Tenenbaum et al, 2004; Gross et al, 2005). Mass spectrometry
and proton (
1H) nuclear magnetic resonance (NMR) spectro-
scopy are the two key experimental methods in the area
of ‘global biochemistry’ (Fernie et al, 2004).
1H NMR, in
particular, is advantageous for screening, as it can efﬁciently
extract detailed molecular information on a large number of
metabolites in various bioﬂuids (Tang et al, 2004; Beckonert
et al, 2007; Ala-Korpela, 2008). The earliest experiments with
plasma have already demonstrated this in type II diabetes
(Nicholsonetal,1984).Recently,wehaveshownthatDKDcan
bedetectedby
1HNMRofserum(Ma ¨kinenetal,2006)andthat
the metabolic syndrome (MetS) can be distinguished by
multivariate methods and
1H NMR spectroscopy (Suna et al,
2007). A similar approach has been applied to cardiovascular
disease, but with limited success (Brindle et al, 2002;
Kirschenlohr et al, 2006). The metabolic changes in type II
diabetes have also been studied by chromatographic methods
(Yang et al, 2004; Wang et al, 2006). Animal models have
provided encouraging results and further justiﬁcation for the
metabonomic NMR approach (Williams et al, 2005; Clayton
et al, 2006; Salek et al, 2007), but more experience from
human populations is needed (Grifﬁn and Nicholls, 2006;
Ala-Korpela, 2007).
In this study, the emphasis is on the metabolic continuum
that underlies the slow and often elusive development of
chronic complications. We focus ﬁrst on DKD due to its high
signiﬁcance inthe treatment andprognosisof diabetic patients
(Gross et al, 2005). Our main goal, however, is to extract a
metabolite manifold that highlights not only DKD, but also
other important clinical and biochemical characteristics and
their complex relationships (Fernie et al, 2004). The combina-
tion of
1H NMR of serum and metabonomic mapping provides
the necessary insight: neuralnetworkanalysis and statistically
veriﬁed visualizations of both the spectroscopic and clinical
data will not only help decision making in clinical environ-
ment, but will also increase the knowledge of multifactorial
disease states that are difﬁcult to pinpoint by reductionist
approaches (Sams-Dodd, 2005; Weckwerth and Morgenthal,
2005; Loscalzo et al, 2007). The newsourceof information can
thenbeusedinpersonalizedriskassessmentasacost-effective
high-throughput alternative to a collection of speciﬁc biomar-
ker assays (Lindon et al, 2006; Ala-Korpela, 2008).
Results
Molecular windows to metabolism
We obtained serum samples from the FinnDiane study to
measure two molecular windows for 613 patients with type I
diabetes. A typical
1H NMR spectrum of human serum is
characterized by broad resonances from the lipid molecules of
lipoprotein particles, such as the  CH3 group of triglycerides,
cholesterol compounds and phospholipids (Figure 1C and D).
This so-called lipoprotein lipids (LIPO) window is a complex
mixture of the aforementioned lipid signals, serum albumin
and albumin-bound fatty acid resonances across the aliphatic
region, and the less intense signals from smaller molecules
such as creatinine, lactate and glucose (Ala-Korpela, 1995,
2008).
To reveal the resonances from smaller molecules, the
spectrometer settings can be altered to suppress most of the
broadresonances while still enabling the detectionof themore
mobile low molecular weight molecules (LMWM). The
LMWM window is dominated by the numerous glucose
resonances between 3.1 and 3.9p.p.m., although some lipid
signalsstillremain(Figure1BandE).Thespectralshapesfrom
both windows share a common axis of chemical shift and are
superimposable, except for the intensity scaling constant. For
example, lactate creates a strong doublet signal around
1.28p.p.m. in the LMWM window, but only small shapes on
top of the wider lipid and albumin resonances in the LIPO
window. On the other hand, most of the molecules with the
 CH3 group contribute to the prominent signal around
0.8p.p.m. in the LIPO window, but only the more mobile
species can be detected in the LMWM window.
Spectral proﬁle of type I diabetes
A self-organizing map (SOM) (Kohonen, 2000) was con-
structed from the
1H NMR data (Figure 1A). The SOM was the
result of reducing the 613 experimental spectra into 9 9¼81
representative spectral models, each of which was assigned to
auniquehexagonalunitonthemapgrid.Subsequently,abest-
matching model was determined for each experiment, thus
each patient had a best-matching unit or a ‘place of residence’
on the map. Localized similarity is the fundamental idea
behind the SOM, that is, neighboring units or the patients
therein are more similar to each other than those from the
opposite sides of the map. In this case, similarity was deﬁned
by the arithmetic multidimensional difference between the
two spectral models; thus, any two neighbors shared more
metabolic characteristics (their spectra looked the same) than
two randomly picked patients, on average.
As the SOM is analogous to a geographic map in all but the
way the patients’ coordinates are assigned, it is possible to use
ordinary demographic methods to visualize the properties of
patientsin differentmetabolicneighborhoods (Supplementary
data 1). Here, we started by coloring the units based on the
percentage of DKD patients within a local population
(Figure 1A). The highest value of 70% can be seen on the
western edge of the map, on the unit at row 5 and column 1
(5,1).Theunitat(2,9)nearthenortheastcornerhasthelowest
percentageofDKD(16%),andislocatedfarfrom(5,1).Infact,
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clustered on the western side, whereas the patients with fewer
complications are concentrated on the northeast corner of
the map.
The typical spectral proﬁle of DKD was examined by
comparing the spectral models at (5,1) and (2,9) to see if any
of the metabolite resonances differed. Each of the spectral
plots, such as Figure 1C, consists of three components. First,
the mean model overall data is depicted as a solid black line to
serve as a constant reference to which the spectral models can
be compared. The second curve alongside the reference is the
unit-speciﬁc spectral model, which was split into orange or
bluesegmentsdependingonwherethemodelexceededorwas
less intensethan thereference.As theﬁrst twocurvesareclose
to each other in terms of absolute intensity, a third curve that
depicts the proportional differences is helpful in revealing any
signiﬁcant changes in intensity. In Figure 1C for instance, the
thirdcurvewas drawn below the twoabsoluteintensitycurves
Figure1
1HNMRspectralproﬁleofdiabetickidneydisease.(A)TheSOMof613 2
1HNMRspectraofserum,coloredaccordingtothepercentageestimateofDKD
within a given map region. Each hexagonal map unit deﬁnes a speciﬁc model spectrum and a corresponding subset of patients, the spectra of which best match the
aforementionedmodel.(B)Thelowmolecularweightmetabolites(LMWM)modelspectrumand(C)thelipoproteinlipidandalbumin(LIPO)modelspectrumforapatient
subsetwithinthe mapunit withthe lowestpercentageof DKD.Thecoloredcurve segmentsindicate the current model, whereas thesolid blackcurve indicates the mean
spectrumover alldata,thus servingasaconstant reference.Thecoloredareasbelow themodel spectrarepresentthe proportional differences oftheunit-speciﬁc model
andthe mean model. (D)The LIPO model and(E) the LMWM model spectrum for patients within a mapunit of the highest DKD percentage. Aninteractive presentation
of the model spectra is available in Supplementary data 3.
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tein lipid resonances at around 0.81, 1.23 and 1.95p.p.m.
show reduced values from the mean, whereas the albumin
background is increased. In Figure 1E, the two creatinine
peaks at 2.98 and 3.99p.p.m. are higher for the DKD region
(5,1). However, looking at just two map locations is not
enough for accurate interpretation; a more global perspective
is required.
Diabetic kidney disease, the metabolic syndrome
and mortality
Amajorityofthepatientsinthisstudyhadeithermicro-(22%)
ormacroalbuminuria (37%),thespatialdistributionsofwhich
arerevealed byclass-speciﬁc colorings in Figure 2A and B. The
macroalbuminuric group (clinically diagnosed with DKD) is
concentrated on the western side of the map (P¼1.2 10
 8),
whereas the diagnostically intermediate microalbuminuric
group does not form any statistically signiﬁcant pattern
(P¼0.077). While the DKD status was determined by urine
albumin excretion, the map was constructed solely based on
the
1H NMR spectra of serum, thus illustrating the systemic
biological connection between the two bioﬂuids.
All-cause mortality in Figure 2C (P¼0.00057) was estimated
based on 8.2±0.6 years of follow-up and scaled to the
percentage of deaths in a decade (number of deaths per 1000
patient years). As expected, there is a clear connection
between DKD and increased mortality, and the highest value
of 25% is observed at (7,1) close to the highest DKD
percentage at (5,1). Additional details are available in Figure
1 in Supplementary data 2.
The MetS(NCEP, 2002;Eckeletal,2005) representsabinary
classiﬁcation according to a clinical scoring system (a score of
3 or more is considered positive) that combines several
components of insulin resistance and obesity (Figure 2D–H).
Patients with the lowest score 1 reside on the northern part of
the SOM with a 42% (P¼1.1 10
 5) occupancy at (1,8), and
those with a score above 3 are tightly concentrated on the
southwestern corner, with hardly any overlap with the ﬁrst
group (P¼1.8 10
 8 for score 4, P¼1.3 10
 7 for score 5).
The SOM colorings indicate strong associations between
DKD, mortality and the MetS, but with subtle differences. For
instance, the ﬁrst two MetS categories split the normoalbumi-
nuric northeastern side, rather than spread evenly to mirror
theDKDgroup(Figure2A,B,DandE).Thehighestpercentage
of DKD at (5,1) does not coincide with the highest MetS scores
at (9,1). Interestingly, a history of macrovascular complica-
tionsinthesepatientsseemtoberelatedmoretotheMetSthan
to DKD (Figure 2I), although the numbers are too small for
statistical signiﬁcance (P¼0.035 for the MVD pattern). Finally,
the highest 10-year mortality of 25% is observed at (7,1) in
Figure 2C, where the MetS and DKD overlap the most.
Confounding factors and treatments
The colorings for age (mean±s.d. 40±11 years), type I
diabetes duration (27±10 years) and gender (311 males, 302
females) show only minor spatial clustering and weak
statistical signiﬁcance (Figure 3A–C). Furthermore, the
observed patterns show little similarity to DKD, the MetS or
MVD in Figure 2, suggesting that the major chronological and
physiological determinants of risk do not confound the
biochemical characteristics.
Most of the patients were on medication or had undergone
laser treatment for DRD. Antihypertensive treatment
(P¼2.7 10
 5) is most common (up to 75%) in those areas
on the western side of the map (Figure 3G), which have a high
percentage of DKD in Figure 2B and elevated blood pressure in
Figure 3D and E, as expected. Furthermore, the same areas
have a high proportion of DRD (P¼0.00027), although the
pattern is more widely dispersed on the southwestern half of
the SOM (Figure 3H). Lastly, patients with the highest MetS
scores have also the widest waist (94cm) in Figure 3Fand the
highest percentage (30%) of lipid-lowering treatment
(Figure 3I).
Biochemical backdrop of diabetic complications
To create a more comprehensive metabolic picture than that in
Figure 1, we colored the map according to estimates from
regression models and spectral features that quantify key
biochemical variables directly from the
1H NMR spectra
(Ma ¨kinen et al, 2006). The previously used null hypothesis
of no dependence betweenthe map and a target variable could
ABC
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Figure 2 Statistical colorings of albuminuria, the MetS, MVD and mortality.
(A–C) Demographic properties of patients on the SOM that was constructed
from 613 2
1H NMR spectra of serum. The three upper plots depict the
clustering of (A) microalbuminuria, (B) macroalbuminuria and (C) 10-year
mortality in patients with type I diabetes. The color of each hexagonal map unit
indicates the estimated proportion of cases with respect to the total number of
patients who reside on the unit in question. For mortality, the estimates were
normalized by follow-up time. (D–H) Five grades of the MetS according to the
NCEP ATP III recommendations and (I) the distribution of patients with a history
of macrovascular events. Empirical P-values for each plot as a whole are shown
below the colorings.
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derived from the spectra. The dynamic range of statistical
ﬂuctuations was nevertheless estimated to determine a
suitable color scale (Supplementary data 1).
TriglycerideconcentrationisapartoftheMetSdeﬁnition,and
the highest unit-speciﬁc value (3.6mmol/l) can therefore be
seen at the southwest cornerof the map, where also the MetS is
most severe (Figure 4A). Total serum cholesterol is only
partially linked to triglycerides, as it produces an ascending
north-south pattern on the SOM (Figure 4B). Nevertheless, the
highestvalue(6.0mmol/l)coincideswiththatoftriglyceridesat
(1,9). HDL2 cholesterol exhibits a more complicated pattern
(Figure 4C), with the highest value (0.64mmol/l) located near
the southeast corner, and the lower values (0.41–0.47mmol/l)
located on the western side.
Creatinine singlets at 2.98 and 3.99p.p.m. and urea around
5.68p.p.m. have a strong association with DKD (Figure 2B)
and produce similar colorings of approximately doubled
values on the western side of the SOM as compared with the
eastern side (Figure 4D and E). Furthermore, lactate at 1.28
and 4.05p.p.m. and acetate at 1.86p.p.m. follow the same
trend (Figure 4G and H), but with patterns closer to the MetS.
Serum albumin is higher on the eastern half of the map
(Figure 4F), which was already evident in the typical spectral
model of DKD in Figure 1C and D.
The effect of the glucose resonances between 3.1 and
3.9p.p.m. was suppressed when constructing the SOM, but
nevertheless the remaining doublet from a-glucose around
5.19p.p.m. was enough to separate patients who had high
blood glucose at the time of sample collection (Figure 4I).
Although the daily variations are large in type I diabetic
patients, high glucose values do partially overlap with the
MetS and other complications on the southwestern half.
Validation by standard biochemistry
Standard non-NMR measurements of a number of metabolites
were also available for validating the NMR-derived results
with methodologically independent data (Table 1 in Supple-
mentary data 2). In addition, the metabolite manifold from
the spectra was supplemented with biomolecular data that
could not be detected by NMR to conﬁrm biologically relevant
observations.
Figure5A–C depicts the three most important lipid variables
(see also the NMR-derived colorings in Figure 4A–C), with
highly statistically signiﬁcant patterns for triglycerides
(P¼3.1 10
 19), total cholesterol (P¼2.1 10
 13) and HDL2C
(P¼2.5 10
 6). HDL3C( P¼4.3 10
 6) has a pattern similar to
HDL2C in Figure 5F. The highest concentration of ApoB
(117mg/dl) coincides with the highest triglycerides and
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Figure 4 Statistical colorings of
1H NMR estimates of biochemical variables.
(A–I) Quantitative estimates of biochemical variables based on the statistical
modeling of the
1H NMR spectra, and visualized on the SOM that was obtained
previously from the same data. Regression model estimates for (A) serum
triglyceride concentration, (B) cholesterol level, (C) HDL2 cholesterol and (D)
serum creatinine. The colorsof the map units indicate the averaged estimates for
patients who reside in a given region. (E) Concentrations of serum urea were
obtained by direct peak integration around 5.68p.p.m. and (E) albumin
concentrationwasestimatedbyparametriclineﬁttinginthealiphaticregionofthe
LIPO window. (G) Lactate signal at 4.05p.p.m. (H) acetate at 1.86p.p.m. and
(I) glucose at 3.44p.p.m. were quantiﬁed by peak integration.
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Figure 3 Statistical colorings of confounding factors and treatments. (A–F)
Clinical characteristics of patients on the SOM of
1H NMR spectra. The colors of
the map units indicate the estimates for the average (A) age and (B) diabetes
duration within the patient subset on a particular map region. (C) The gender
distributionsonthemapunits.Thecolorofeachhexagonalmapunitindicatesthe
percentageofmalegenderwithrespecttothetotalnumberofpatientsthatreside
on the unit in question. (D, E) Blood pressure and (F) waist circumference for the
patient subsets within each map unit. The percentages of (G) antihypertensive
treatment, (H) DRD and (I) lipid-lowering treatment were obtained as described
above.
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elevated if either of the two is higher than average
(P¼1.1 10
 13 for ApoB).
Creatinine is easily detectable by
1H NMR as two singlets at
2.98 and 3.99p.p.m; accordingly, the non-NMR measurement
in Figure 5D closely matches the NMR-derived creatinine
(and biologically correlated urea) in Figure 4D and
E( P¼9.2 10
 7). The 24h-urine albumin in Figure 5I is
indicative of persistent albuminuria by deﬁnition
(P¼4.6 10
 10), and albuminuria is tightly linked to the
metabolite manifold from NMR, as was evident in Figure 2A
and B.
Patients in the southwest corner have signiﬁcantly higher
weight-adjusted insulin doses (P¼0.00053), but, despite that,
the worst glycemic control, which is indicated by HbA1c of
9.7% (P¼2.9 10
 8). Corresponding patterns were previously
observed for the MetS (Figure 2F–H) and NMR-derivedlactate,
acetate and glucose (Figure 4G–I), which can be seen as an
indication of insulin resistance.
Summary of clinical and metabolic characteristics
Intheﬁnal stage, we merged mapunits into largerdistrictsand
collected the regional characteristics into tabular format to
create a summary of the metabolic characteristics (Figure 6;
Table 3 in Supplementary data 2). For instance, the southwest
district (Figure 6A) is populated by patients with high relative
risk due to DKD and the MetS (7.8 versus 2.0–2.1), compared
ABC
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Figure5 Validationofthebiochemicalaccuracyofthe
1HNMRdataandneural
network analysis. (A–I) Measurements of clinical markers by standard (non-
NMR) biochemistry, visualized on the SOM of
1H NMR spectra. (E)
Apolipoprotein B-100, (F) HDL3 cholesterol, (G) insulin dose, (H) glycemic
control and (I) 24h-urine albumin were included instead of those metabolites
from Figure 4 that were estimated by
1H NMR.
Figure 6 Summary of clinical and metabolic characteristics. (A–F) Statistics for a selection of non-NMR variables for patient groups deﬁned by six districts on the
SOM. Themapwasconstructed basedon the
1H NMRspectra for613 typeIdiabetic patients. Thepercentages ofcases withrespectto the totalnumber ofpatients ina
given district and for the whole population (ALL) are listed for 10-year mortality (normalized by follow-up time), DKD, the MetS, MVD, DRD and male gender. Relative
risk of death (RR) was deﬁned as the ratio of the observed mortality in type I diabetic patients against the entire Finnish population. The MetS was deﬁned as present
if the score was three or more. Median values are listed for the continuous variables, with the full statistics available for the non-NMR data in Table 3 in Supplementary
data 2.
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Biochemically, these groups differ signiﬁcantly: triglycerides
(2.8 versus 0.84mmol/l), cholesterol (5.8 versus 4.5–
4.9mmol/l), serum creatinine (116 versus 87–88mmol/l)
and 24h-urine albumin (356 versus 13–16mg) are high,
whereas HDL-subfractions are low in the MetS district.
Patients in the MetS corner have also poor glycemic control
(HbA1c 9.2 versus 8.2%) and larger waist circumference (94
versus 81–83cm).
The northwest corner is characterized by high susceptibility
to microvascular complications, as DKD (58%) and DRD
(58%) are common but MetS (42%), MVD (10%) and 10-year
mortality (17%) are closer to average. Furthermore, there is a
notable difference in HDL2C when comparing the northwest
corner and the southeast corner of the SOM (0.45 versus
0.60mmol/l), which is also visible in Figure 4C. On the other
hand, total cholesterol is higher in the southeast (4.9 versus
5.7mmol/l), so the difference in the ratio of HDL2 to total
cholesterol is less pronounced.
The two districts with favorable phenotypes are similar if
complications alone are considered, but some minor biochem-
ical differences can be observed (Figure 6E and F). Although
both districts share relatively high HDL2C concentrations,
ApoA1, ApoB, HDL3C and total cholesterol are lower in the
northern district. The districts arealso different with respect to
serum albumin (Figure 4F). Triglycerides and glycemic control
(HbA1c 8.2%) exhibit no clear differences, as was seen also in
the spectral estimates of triglycerides in Figure 4A.
Discussion
Diabetes is associated with increased incidence of vascular
complications and premature aging (Morrish et al, 2001;
Ro ¨nnback et al, 2005; Pambianco et al, 2006). Here, we
characterized the metabolic background of adverse clinical
phenotypes within this high-risk population by
1H NMR
spectroscopy of serum. Speciﬁcally, we were able to identify
differences and similarities in the biochemical patterns of
DKD, insulin resistance, DRD, macrovascular complications
and all-cause mortality in 613 type I diabetic patients.
The
1H NMR analyses were targeted at two molecular
windows simultaneously. The LIPO window carries informa-
tion particularly on lipoprotein lipids and albumin, whereas
the LMWM window contains signals from smaller metabolites
such as creatinine and glucose (Ma ¨kinen et al, 2006; Ala-
Korpela, 2008). Lipoprotein levels arealtered in type I diabetes
in the presence and during the development of complications
(Chaturvedi et al, 2001; Lyons et al, 2004; Thomas et al, 2006),
but they alone cannot capture all aspects of the diabetic
condition. It is therefore plausible that the inclusion of the
LMWM windowas an integralpart of the biochemical analysis
is crucial for polydiagnostic applications that are targeted at
several concurrent disease mechanisms (Kell, 2006).
The raw metabolite manifold obtained from the two
molecular windows was not usable as such, but multivariate
computational analysis was required to transform the spectral
datainto anaccessibleform of information. Wechose theSOM
(Kohonen, 2000; Suna et al, 2007) instead of linear decom-
positionmethodssuchasprincipalcomponentanalysis(PCA),
since the SOM algorithm preserves the spectral shapes and
summarizes the data via a small number of spectral models
that aredirectly relatable to individual samples (Figure 1). The
decompositions, on the other hand, are focused on the
variables and on the reduction of the data into abstract
multidimensional linear spaces that may not have a direct
connection to the observed NMR resonances.
PCA and partial least squares methods have been estab-
lished as the standard pattern recognition methods in the ﬁeld
of metabonomics (Dieterle et al, 2006; Trygg et al, 2007).
However, the SOM analysis has been applied, for instance, in
spectroscopic classiﬁcation problems (Beckonert et al, 2003;
Lavine et al, 2004; Suna et al, 2007), in molecular conforma-
tion analysis (Hyvo ¨nen et al, 2001) and in studies of gene–
metabolite interactions (Hirai et al, 2004). The last case is an
example of complementary application of both PCA and SOM.
Some studies have also compared SOM with other methods
(Mangiameli et al, 1996; Giraudel and Lek, 2001; Astel et al,
2007) and, in most cases, the use of SOM produced additional
insight compared with PCA (see also Supplementary data 1).
The ambiguity in model selection and the danger of
overﬁtting are the main drawbacks of neural network
algorithms (Lampinen and Kostiainen, 1999). Here, the
statistical signiﬁcance of the observed patterns was addressed
from a practical point of view, with emphasis on the ability of
1H NMR to extract relevant metabolic information from a
serum sample. The question of overtraining was not relevant
in this context, as we were not using the SOM as a predictive
tool but included only the spectra as inputs. Thus, we were
able to integrate different sources of data in a user-friendly
fashion by stochastically normalized map colorings, without
giving up statistical reliability.
We chose not to perform supervised feature extraction or
selection before the SOM analysis. This may have led to
suboptimal predictive performance for a particular clinical
endpoint but, ontheotherhand, theresults reﬂect the intrinsic
metabolic information content of the spectra as such, and the
complexdependencies betweenthevarious bodies of data. For
instance, we have previously shown that a linear regression
model with nonlinear feature extraction can indicate the
albumin excretion categories from the
1H NMR spectra of
serum (Ma ¨kinen et al, 2006), but this model has less utility in
nondiabeticpopulations.The SOMpresentedhere,however,is
not methodologically dependent on albuminuria and thus
easier to relate to the general population.
Omitting explicit feature selection does not guarantee
optimal results, but other options would require detailed
methodological treatment that is not yet available, and might
complicate the interpretations of the original spectral shapes.
DKD, for instance, is a discrete classiﬁcation based on one
biomarker (urine albumin), and while it makes a perfect test
case for analytical techniques (Ma ¨kinen et al, 2006), a systems
biology approach to diabetic complications should not aim to
predict albuminuria, but to distinguish the multifactorial
disease states, even if not all of them are associated with overt
albuminuria (Caramori et al, 2006). Put differently, a
predictive model will only work in the clinical practice if the
phenotype to be predicted is accurate (Loscalzo et al, 2007).
Despite the shortcomings, albumin excretion is an excellent
indicatorofprogressingkidneydamageaftertheearlystagesof
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15 years of diabetes (Gross et al, 2005; Caramori et al, 2006);
patients included in this workhad a long diabetes duration (26
years on average), so the normoalbuminuric subgroup has a
low riskof everdeveloping DKD. Consequently, theyrepresent
a generally healthier subset of diabetic patients, especially
when considering that low-grade albuminuria is associated
with macrovascular complications, even outside type I
diabetes (Gerstein et al, 2001). Still, normoalbuminuria does
not preclude the cardiovascular risk factors: a signiﬁcant
portion of patients in the map region with dyslipidemia and
insulin resistance (Figure 6A) had normal (17%) or inter-
mediate (20%) albumin excretion as opposed to macroalbu-
minuria (63%).
The metabolic differences between most normo- and
macroalbuminuric (DKD) patients were evident in the
1H
NMR spectra of serum. DKD was associated with elevated
triglycerides, lower HDL cholesterol and decreased albumin in
the LIPO window. Other studies have also reported the
connection between albuminuria and triglycerides (Chaturve-
di et al, 2001; Jenkins et al, 2003; Thomas et al, 2006), but the
exact role of HDL metabolism remains unclear. Serum
creatinine and urea are two waste products that are normally
excreted by the kidneys and, accordingly, the LMWM window
revealed elevated values for the macroalbuminuric group,
although none of the patients had end-stage renal disease.
Crucially, the microalbuminuric patients did not clearly
identify with either the low-risk or high-risk regions of the
SOM, again highlighting the limited usefulness of any single
biomarker in complex disease environments (Caramori et al,
2000).
The MetS and DKD are strongly associated in the Finnish
type I diabetic population (Thorn et al, 2005). Our results from
the metabonomic analysis were similar: the SOM regions with
patients that have a detectable loss in kidney function (i.e.,
elevated creatinine and urea, decreased serum albumin)
overlapped with insulin resistance and related problems in
glucose metabolism (dyslipidemia, high insulin dose, high
HbA1c, elevated lactate and acetate and high fasting glucose)
(Krentz et al, 1991; Lovejoy et al, 1992; Avogaro et al, 1996;
Choi et al, 2002). Interestingly, the neighborhood with the
most severe insulin resistance did not coincide with the
highest values of creatinine and urea, which suggests that
there is a subtle systematic difference between the two clinical
conditions. Furthermore, the highest mortality was observed
on the intersection of the two defects. Unfortunately, the data
set size in this study was insufﬁcient for any deﬁnitive
conclusions, but we have made similar observations with the
non-NMR data for the full FinnDiane population (Ma ¨kinen
et al, in preparation), so these results nevertheless support a
multifactorial approach to the study of pathophysiology
(Loscalzo et al, 2007).
The discrepancy between the MetS and DKD could not be
explained by nonbiochemical factors. For instance, although
lipid treatment was most common in the MetS neighborhood,
this group of patients still had the highest triglyceride
concentration. Thissuggests that DKD with lower triglycerides
is not a product of lipid-lowering treatment alone. In contrast,
the highest percentage of antihypertensive treatment coin-
cided with the highest blood pressure and DKD, but not with
the MetS, which in turn suggests that the MetS with
lower albumin excretion is not just a product of
decreased albuminuria due to blood pressure medication
(Thomas and Atkins, 2006). Furthermore, there was
little regional gender difference in the MetS-DKD half of
the SOM, so the wide waist circumference in the MetS
neighborhood did not represent a gender bias. Hence, our
results did not match some of the previous ﬁndings on
statistical gender groupings in
1H NMR experiments of plasma
(Kirschenlohr et al, 2006).
Macrovascular events are the primary targets of interven-
tion,astheyarethemostcommoncause ofprematuredeathin
type I diabetic patients (Libby et al, 2005; Stadler et al, 2006).
In this respect, the difference between insulin resistance and
kidney function becomes signiﬁcant; the SOM neighborhood
with the highest percentage of MVD was also the one with the
strongestinsulinresistanceandthehighestMetSscores,which
agrees well with previous studies (Sierra-Johnson et al, 2006).
The result is only suggestive, as the numbers were low and we
had only cross-sectional data on MVD available, but this
ﬁnding nevertheless demonstrates the sensitivity of the
metabonomics approach to MVD vulnerability, as opposed to
thealbuminuriaclassiﬁcationalone.Undoubtedly,triglyceride
concentration is the most signiﬁcant serum biomarker (Davis
et al, 2007; Pambianco et al, 2007), and its role may be even
further emphasized here, as triglycerides produce pronounced
1H NMR resonances.
DRD was the most common (51%) complication among the
study population. Map regions with DKD or insulin resistance
hallmarks had the highest percentages, but DRD did not
speciﬁcally associate with either of the two. The connection to
mortality was less obvious due to the large number of DRD
cases, which agrees with previous observations (Torffvit et al,
2005).
Low concentration of HDL2 cholesterol was the common,
albeit not exclusive, denominator for all complications, which
suggests that HDL2 has a protective effect, or is a marker of a
favorable phenotype with respect to both micro- and macro-
vascularcomplications (Cutri et al, 2006). This isin contrast to
manyobservations regarding type I diabetes (Chaturvedi et al,
2001; Jenkins et al, 2003; Thomas et al, 2006), but the
disconnect may be due to the statistical models that were used
in these studies. There is a negative correlation between HDL
cholesterol and serum triglycerides, so any linear model that
includes boththe twois likelyto emphasizeone atthe expense
of the other. Furthermore, men and women have different
concentrations,so gender bias is likelyto inﬂuence the results.
To resolve the controversy, studies that use modern multi-
variate pattern recognition techniques in addition to the
classical medical statistics should be performed on large
population-based cohorts.
The biological heterogeneityof diabetic complications make
the borderline between health and disease ambiguous, as is
the case with many other slow pathophysiological processes.
Our work illustrates this fundamental diagnostic challenge:
DKD, DRD, the MetS and MVD shared much of the same
biochemical basis, but nevertheless did not conclusively
deﬁne each other. Even though the patients in this study were
carefully selected to represent clinically relevant phenotypes,
the metabolic landscape remained diffuse.
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study on premature death and vascular complications in a
large human cohort. We used only serum to characterize the
patients, and yet the high-risk metabolic features were easily
observable. This is an encouraging result with respect to
general applicability as, unlike type I diabetes, urine albumin
(or any other single biomarker) does not have an equally
critical role in type II diabetes, let alone in the nondiabetic
population. Furthermore, our application of
1H NMR metabo-
nomics and statistical visualizations mayimprovethe tracking
of patients’ progress in the diabetic disease continuum in a
way not attainable by traditional approaches. Hence, it may
become possible to re-route the multimetabolite path of a
vulnerable patient away from adverse clinical endpoints
and towards a more favorable phenotype before it is too late
(Ala-Korpela et al, 2006).
Materials and methods
Study population
Patients with type I diabetes were recruited by the Finnish Diabetic
Nephropathy Study (FinnDiane), which is a nationwide multicenter
effort to identify genetic and clinical risk factors for DKD. The study
protocol was in accordance with the Declaration of Helsinki and
approved by the local ethics committee in each of the participating
health care centers. Diagnostic criteria for type I diabetes included age
ofonsetbelow35,thetransitiontopermanentinsulintreatmentwithin
a year from onset and C-peptide negativity.
Data on medication, cardiovascular status and diabetic complica-
tions were registered by a standardized questionnaire, which
was completed by the patient’s attending physician according to
the medical ﬁle. Death certiﬁcates were obtained from the national
registry maintained by the Population Register Centre of Finland.
The average follow-up time was 8.2±0.6 years (4972 patient years
in total).
The classiﬁcation of renal status was made centrally according to
urinary albumin excretion rate (AER) in at least two out of three
successive overnight urine samples. Absence of kidney disease
was deﬁned as normoalbuminuria (AERo20mg/min), while the pre-
sence of overt kidney disease was deﬁned as macroalbuminuria
(AERX200mg/min). The intermediary range is referred simply as
microalbuminuria (20mg/minpAERo200mg/min). Albumin from
24h-urine samples was also available, and it was used as a
biochemical variable in parallel with the longitudinal records of
albuminuria.
The MetS scores were calculated according to the NCEP ATP III
recommendations (NCEP, 2002), with every type I diabetic patient
having a base score of 1 for hyperglycemia (Table 2 in Supplementary
data 2). DRD was deﬁned present if a patient had undergone laser
eye treatment. MVD was deﬁned as a pooled composite of coronary
heart disease, acute myocardial infarction, stroke and peripheral
vascular disease. The events were pooled to have more cases for the
statistical analyses. Of the 54 cases, 40 had coronary heart disease,
24 had acute myocardial infarction, 12 had undergone coronary
bypass, 15 had cerebral stroke and 17 had undergone peripheral
vascular bypass.
Patients for the
1H NMR experiments were chosen based on the
renal status. First, a random subset of macroalbuminuric patients was
selectedfromtheFinnDianeclinicaldatabasewithpreferenceforthose
individuals with genetic and clinical information already available.
Next, sex- and age-matched peers were chosen from the normo- and
microalbuminuric group, with preference for normoalbuminuria and
availability of information. In total, 613 patients were included, of
which 251 (41%) were normoalbuminuric, 137 (22%) had micro-
albuminuriaand225(37%)hadmacroalbuminuria.Patientswithend-
stage renal disease or kidney transplant were excluded. The study set
does not reﬂect the population-based cross-section, except within the
macroalbuminuric group.
1H NMR spectroscopy
1H NMR data from serum samples at 371C were recorded on a Bruker
AVANCE spectrometer with a ﬁeld strength of 500.13MHz. The
reference substance (sodium 3-trimethylsilyl[2,2,3,3-d4]propionate
(TSP) 40mmol/l, MnSO4 0.6mmol/l in 99.8% D2O) was placed
coaxiallyintotheNMRsamplecontainer(o.d.5mm,contains430mlof
serum)inaseparatetube(o.d.1.7mm,supportedbyaTeﬂonadapter).
This double-tube system was chosen to avoid mixing of the sample
ﬂuid and reference substance, which would make the absolute
metabolite quantiﬁcation less reliable (Ala-Korpela, 1995, 2008;
Ma ¨kinen et al, 2006).
The
1H NMR experiments were targeted at two different molecular
windows: LIPO and LMWM. For the LIPO spectra, 128 transients were
collected with a 901 ﬂip angle, a 6.2s acquisition time and a 0.1s
relaxation delay. The LMWM data were collected with a standard one-
dimensional Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with
a 325ms T2-ﬁlter and a ﬁxed 400ms echo delay to eliminate diffusion
and J-modulation effects. Forty-eight transients were collected after 16
dummy scans with a 6.2s acquisition time and an 8.7s relaxation
delay. Water suppression was not used. The free induction decays
(FID) with 65536 data points were zero-ﬁlled and multiplied by an
exponential window function with a 1.0Hz line-broadening for the
LIPO spectra and 0.5Hz line-broadening for the LMWM spectra. The
preprocessing of the FIDs and subsequent Fourier transformations
were performed on the PERCH software platform (PERCH Solutions
Ltd, Kuopio, Finland).
Metaboliteintensitiesineachspectrumwerescaledaccordingtothe
area of the respective TSP reference signal at 0p.p.m.. The TSP area
was obtained by ﬁrst subtracting the linear baseline between  0.1 and
0.1p.p.m., and then integrating over the remainder. In the LMWM
window, the effects of the water peakaround 4.6p.p.m. were removed
by ﬁtting a Lorenzian tail on the aliphatic side and a piece-wise
polynomial curve on the aromatic side, and then subtracting the tails.
Furthermore, a minor piece-wise linear correction was applied in both
windows,mainlyaffecting the region between3 and5p.p.m..Peaks in
the LMWM spectra were aligned by ﬁrst estimating the shift offsets at
selected locations, then linearly interpolating the offsets where direct
peak detection was difﬁcult and ﬁnally re-mapping the frequency axis
according to the estimated shift offsets. The same correction was
performed also for the LIPO spectra, although the effects were small
due to wider line shapes. All preprocessing was performed in the
Matlab programming environment (The MathWorks Inc., Natick, MA,
USA) by using the statistical toolbox and in-house scripts.
Self-organizing map and statistical analysis
Before constructing the SOM, the spectra were truncated to
0.3–3.3p.p.m. (LIPO) and 0.7–5.8p.p.m. (LMWM), and the chemical
shift resolution was reduced to 0.003p.p.m. (LIPO) and 0.001p.p.m.
(LMWM). Data points between 4.2 and 5.0p.p.m. were omitted and
the intensities between 3.22 and 3.88p.p.m. were given only 0.1%
weight in the SOM algorithm to attenuate the effect of glucose. The
respective intensity units for the two molecular windows were
adjusted such that the total variance of the data points within the
LIPO window was equal to that in the LMWM window. This was
done to ensure that both windows would have comparable effect to
the SOM structure while preserving the relative intensities between
individual experiments.
We chose a 9 9 hexagonal sheet of map units with a Gaussian
neighborhood function for the analysis (7.6 samples per unit). The
SOM was initialized based on the two ﬁrst principal components of the
input data and ﬁnished by the batch-training algorithm, with a 3.4%
topological error.
AfterthepositionsofthestudysubjectsontheSOMwerecomputed,
the map was colored according to the demographic properties (i.e.,
clinical and biochemical variables) within different parts of the SOM
(Supplementary data 1). To verify statistical signiﬁcance, regional
variability for the colorings was estimated by ﬁrst computing the
squareddeviationsfromtheglobalaverageforeachmapunit,andthen
addingtheseunit-speciﬁcvaluestoobtainasingledescriptivestatistic.
Put differently, the ‘bumpiness’ of a coloring was expressed as one
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estimatethe expected null distribution, the target variable (DKD status
for instance) was shufﬂed randomly several times, and at each round,
the descriptive statistic was recomputed. The probabilityof getting the
observed statistic (or a more extreme value) from the random
distribution determined the statistical signiﬁcance P. The null
distributions from the permutation analysis were also the basis of
the color scale in each ﬁgure so that categorical and continuous
variables, possibly with some data missing, can be compared visually
while maintaining the statistical interpretation.
MortalityinFigure2Cwasestimatedbyﬁrst computingthecoloring
for the percentage of deaths observed on each map unit, and then
normalizingthesevaluesbytheaverageunit-speciﬁcfollow-uptimein
decades. Note that this is equivalent to the number of deaths in 1000
patient years. Only patients that had not died (91%) were used for the
follow-up time estimation to avoid bias due to deaths. The unadjusted
event percentages and follow-up times are available in Figure 1 in
Supplementary data 2. The discrepancy between Figures 2C and 6A
(max 25 versus 26%) stems from different formulations: the former
was obtained from the smoothed map estimates for the number of
deaths and follow-up period, whereas the latter was obtained from
point estimates within the resident patient subgroup. Relative risk for
earlydeathinFigure6wasobtainedastheratioofobserveddeathsand
the mortality in the corresponding age segments of the entire Finnish
population within the follow-up period (data from Statistics Finland).
In addition to clinical variables, numerous quantities were
estimated computationally from the spectral data. Easily distinguish-
able peaks in the LMWMwindowsuch as ureaaround 5.68p.p.m. and
acetate at 1.86p.p.m. were quantiﬁed by direct peak integration. The
wide baseline signal from serum albumin was estimated by ﬁtting a
polynomial curve at selected locations in the LIPO window and
computing the respective curve area. Lastly, semilinear regression
modeling was applied to quantities that were also available via non-
NMR methods (Ma ¨kinen et al, 2006). All analyses were performed
using the SOM Toolbox 2.0 for the Matlab environment (URL: http://
www.cis.hut.ﬁ/projects/somtoolbox/), and in-house scripts for sub-
sequent quantiﬁcation, map coloring and permutation analyses.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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